CATALOGO DEI PRODOTTI DELLA RICERCA

MILELLA, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.272
EU - Europa 14.120
AS - Asia 11.469
SA - Sud America 1.818
Continente sconosciuto - Info sul continente non disponibili 571
AF - Africa 395
OC - Oceania 44
AN - Antartide 1
Totale 43.690
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.803
RU - Federazione Russa 6.336
SG - Singapore 4.871
CN - Cina 2.635
IT - Italia 2.056
BR - Brasile 1.437
GB - Regno Unito 1.145
HK - Hong Kong 1.124
VN - Vietnam 1.064
DE - Germania 950
FR - Francia 908
IE - Irlanda 725
SE - Svezia 599
FI - Finlandia 505
KR - Corea 385
BD - Bangladesh 331
CA - Canada 249
NL - Olanda 224
IN - India 220
ID - Indonesia 208
AR - Argentina 129
JP - Giappone 117
PL - Polonia 114
MX - Messico 110
ES - Italia 109
UA - Ucraina 105
AT - Austria 94
ZA - Sudafrica 84
TR - Turchia 73
IQ - Iraq 71
EC - Ecuador 55
BJ - Benin 53
CO - Colombia 53
TG - Togo 51
NG - Nigeria 49
VE - Venezuela 43
AU - Australia 40
CZ - Repubblica Ceca 39
PK - Pakistan 39
EG - Egitto 30
MA - Marocco 30
UZ - Uzbekistan 30
SA - Arabia Saudita 29
TH - Thailandia 29
CL - Cile 28
IR - Iran 25
PY - Paraguay 25
BE - Belgio 24
CH - Svizzera 23
JO - Giordania 23
LT - Lituania 22
MY - Malesia 22
TN - Tunisia 22
AE - Emirati Arabi Uniti 20
CR - Costa Rica 20
PH - Filippine 20
UY - Uruguay 20
JM - Giamaica 18
NP - Nepal 18
PE - Perù 18
KZ - Kazakistan 15
DZ - Algeria 13
HN - Honduras 13
KE - Kenya 13
AZ - Azerbaigian 12
HR - Croazia 12
KG - Kirghizistan 12
PT - Portogallo 12
RS - Serbia 12
GT - Guatemala 11
LV - Lettonia 11
SN - Senegal 11
IL - Israele 10
RO - Romania 10
AM - Armenia 9
DO - Repubblica Dominicana 9
GR - Grecia 9
SK - Slovacchia (Repubblica Slovacca) 9
TT - Trinidad e Tobago 9
AL - Albania 7
AO - Angola 7
BG - Bulgaria 7
BO - Bolivia 7
BY - Bielorussia 7
CY - Cipro 7
DK - Danimarca 7
EU - Europa 7
LU - Lussemburgo 7
NO - Norvegia 7
PS - Palestinian Territory 7
SV - El Salvador 7
TW - Taiwan 7
ET - Etiopia 6
MK - Macedonia 6
PA - Panama 6
KH - Cambogia 5
SI - Slovenia 5
SY - Repubblica araba siriana 5
BH - Bahrain 4
HU - Ungheria 4
Totale 43.043
Salva come PNG Salva come JPEG
Città #
Singapore 2.480
Ashburn 2.157
Moscow 2.052
Dallas 1.817
San Jose 1.771
Chandler 1.265
Hong Kong 1.108
Council Bluffs 796
Verona 791
Southend 738
Dublin 697
Beijing 522
The Dalles 454
Ho Chi Minh City 352
Munich 346
Woodbridge 334
New York 327
Jacksonville 308
Los Angeles 301
Lawrence 267
Princeton 267
Hanoi 225
Helsinki 205
Houston 199
Ann Arbor 197
Sindelfingen 185
Buffalo 171
Milan 168
Santa Clara 162
Jakarta 156
São Paulo 154
Redondo Beach 150
Redmond 139
Wilmington 137
Jinan 136
London 124
Tokyo 101
Frankfurt am Main 92
Turku 91
Chicago 86
Nanjing 84
Orem 84
Columbus 83
Shenyang 83
Montreal 81
Toronto 75
Nuremberg 74
Lappeenranta 72
Tianjin 69
Amsterdam 68
Warsaw 68
Seattle 65
Hebei 61
Atlanta 59
Da Nang 58
Meda 58
Johannesburg 57
Rome 57
Brooklyn 55
Cotonou 53
Lomé 51
Chennai 49
Guangzhou 49
San Francisco 49
Ningbo 46
Stockholm 46
Vienna 46
Abuja 45
Changsha 45
Denver 45
Rio de Janeiro 45
Seoul 45
Phoenix 43
Zhengzhou 40
Belo Horizonte 39
Mumbai 39
Boardman 38
Haiphong 37
Boston 36
Hangzhou 36
Poplar 36
Mexico City 35
Naples 35
Shanghai 35
Washington 35
Paris 33
Bologna 31
Haikou 31
Kent 31
Nanchang 31
Baghdad 30
Barnet 30
Falkenstein 30
Taiyuan 30
Dong Ket 29
Madrid 29
Biên Hòa 28
Tashkent 28
Ankara 26
Curitiba 26
Totale 24.880
Salva come PNG Salva come JPEG
Nome #
Assessment of Psychological Burden in Individuals with Hereditary Risk of Pancreatic Cancer Under Surveillance: Evaluation of Distress 3 Years After Enrollment 342
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 314
Genomic characterization of hepatoid tumors: context matters 261
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 258
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 252
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 219
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models 217
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 215
Long-Term Survivor of Intrahepatic Cholangiocarcinoma for over 18 Years: Case Study with Longitudinal Histo-molecular and Tumor Immune Microenvironment Characterization and Systematic Review of the Literature 214
Treatment of locally advanced rectal cancer in the era of total neoadjuvant therapy: a systematic review and network meta-analysis 214
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 212
Sex differences in oncogenic mutational processes 206
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma 206
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 205
Acinar Cystic Transformation of the Pancreas: Histomorphology and Molecular Analysis to Unravel its Heterogeneous Nature 203
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 202
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 201
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 200
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 198
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 195
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 195
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 194
A multimodal approach to cancer-related cachexia: from theory to practice 194
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 193
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 189
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 187
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 187
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer 186
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 182
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 181
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 181
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 181
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss 180
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 180
ERK 1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 179
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 178
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar 178
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 177
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 175
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 174
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen 173
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 173
Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis 170
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 170
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 170
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 168
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 168
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 167
Loss of FGFR4 promotes the malignant phenotype of PDAC 167
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma 166
Exercise levels and preferences in cancer patients: a cross-sectional study 166
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 166
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 166
Do immune checkpoint inhibitors need new studies methodology? 165
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 165
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 165
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 165
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 164
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 164
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 162
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 162
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 161
A cross-sectional study exploring the perception of exercise oncology in the Italian population 160
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 159
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 159
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 159
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 159
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 159
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 158
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions 158
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 158
Pan-cancer analysis of whole genomes 156
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 156
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial 156
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 155
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 155
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 155
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 154
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 154
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 153
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 153
Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization 152
Muscle derangement and alteration of the nutritional machinery in NSCLC 152
Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients 151
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 151
Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites 151
A Journey through the Multifaceted Landscape of Prostate Cancer: from Bench to Bedside Studies 151
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 150
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias 149
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 148
Case report: Male genital system, soft tissue and myocardial metastases in a patient with exon 11-mutated GIST of unknown origin 148
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 147
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 147
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 147
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 146
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 146
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona 146
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 146
Exploring the Association between Health-Related Physical Fitness and Quality of Life in Patients with Cancer: A Cross-Sectional Study 145
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 145
Totale 17.662
Salva come PNG Salva come JPEG
Categoria #
all - tutte 172.259
article - articoli 170.709
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 450
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.100
Totale 344.518
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.679 0 378 60 108 46 22 37 103 59 37 310 519
2022/20234.070 290 364 383 714 323 1.057 61 223 440 49 105 61
2023/20242.607 91 167 234 360 225 356 206 191 56 126 419 176
2024/20257.962 438 354 332 1.393 349 302 437 439 1.112 629 730 1.447
2025/202623.207 1.501 1.258 2.031 3.586 5.544 1.347 2.020 1.367 1.845 1.366 566 776
2026/2027980 380 600 0 0 0 0 0 0 0 0 0 0
Totale 43.690